Curtin University Homepage
  • Library
  • Help
    • Admin

    espace - Curtin’s institutional repository

    JavaScript is disabled for your browser. Some features of this site may not work without it.
    View Item 
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item

    Statins: Antimicrobial resistance breakers or makers?

    Access Status
    Open access via publisher
    Authors
    Ko, H.
    Lareu, Ricky R.
    Dix, B.
    Hughes, J.
    Date
    2017
    Type
    Journal Article
    
    Metadata
    Show full item record
    Citation
    Ko, H. and Lareu, R.R. and Dix, B. and Hughes, J. 2017. Statins: Antimicrobial resistance breakers or makers?. PeerJ. 2017 (10).
    Source Title
    PeerJ
    DOI
    10.7717/peerj.3952
    ISSN
    2167-8359
    School
    School of Pharmacy
    URI
    http://hdl.handle.net/20.500.11937/58468
    Collection
    • Curtin Research Publications
    Abstract

    © 2017 Ko et al. Introduction. The repurposing of non-antibiotic drugs as adjuvant antibiotics may help break antimicrobial resistance (AMR). Statins are commonly prescribed worldwide to lower cholesterol. They also possess qualities of AMR 'breakers'', namely direct antibacterial activity, synergism with antibiotics, and ability to stimulate the host immune system. However, statins' role as AMR breakers may be limited. Their current extensive use for cardiovascular protection might result in selective pressures for resistance, ironically causing statins to be AMR'makers'' instead. This review examines statins' potential as AMR breakers, probable AMR makers, and identifies knowledge gaps in a statin-bacteria-human-environment continuum. The most suitable statin for repurposing is identified, and a mechanism of antibacterial action is postulated based on structure-activity relationship analysis. Methods. A literature search using keywords 'statin' or 'statins' combined with 'minimum inhibitory concentration'' (MIC) was performed in six databases on 7th April 2017. After screening 793 abstracts, 16 relevant studies were identified. Unrelated studies on drug interactions; antifungal or antiviral properties of statins; and antibacterial properties of mevastatin, cerivastatin, antibiotics, or natural products were excluded. Studies involving only statins currently registered for human use were included. Results. Against Gram-positive bacteria, simvastatin generally exerted the greatest an- tibacterial activity (lowest MIC) compared to atorvastatin, rosuvastatin, and fluvastatin. Against Gram-negative bacteria, atorvastatin generally exhibited similar or slightly better activity compared to simvastatin, but both were more potent than rosuvastatin and fluvastatin. Discussion. Statins may serve as AMR breakers by working synergistically with existing topical antibiotics, attenuating virulence factors, boosting human immunity, or aiding in wound healing. It is probable that statins' mechanism of antibacterial activity involves interference of bacterial cell regulatory functions via binding and disrupting cell surface structures such as wall teichoic acids, lipoteichoic acids, lipopolysaccharides, and/or surface proteins. The widespread use of statins for cardiovascular protection may favor selective pressures or co-selection for resistance, including dysbiosis of the human gut microbiota, sublethal plasma concentrations in bacteremic patients, and statin persistence in the environment, all possibly culminating in AMR. Conclusion. Simvastatin appears to be the most suitable statin for repurposing as a novel adjuvant antibiotic. Current evidence better supports statins as potential AMR breakers, but their role as plausible AMR makers cannot be excluded. Elucidating the mechanism of statins' antibacterial activity is perhaps the most important knowledge gap to address as this will likely clarify statins' role as AMR breakers or makers.

    Related items

    Showing items related by title, author, creator and subject.

    • In vitro antibacterial effects of statins against bacterial pathogens causing skin infections
      Ko, H.; Lareu, R.; Dix, B.; Hughes, Jeff (2018)
      © 2018 Springer-Verlag GmbH Germany, part of Springer Nature With financial considerations impeding research and development of new antibiotics, drug repurposing (finding new indications for old drugs) emerges as a feasible ...
    • Investigating the Relationship Between Statins and Bacterial Skin Infections
      Ko, Hean Teik Humphrey (2019)
      Statins are extensively prescribed medicines to reduce cholesterol for cardioprotection, but they also exhibit antimicrobial and pleiotropic effects, which plausibly reduces both skin infection risks and antimicrobial ...
    • Use of a primary epithelial cell screening tool to investigate phage therapy in cystic fibrosis
      Trend, S.; Chang, B.J.; O'Dea, M.; Stick, S.M.; Kicic, Anthony (2018)
      © 2007 - 2018 Frontiers Media S.A. All Rights Reserved. Antimicrobial-resistant microbes are an increasing threat to human health. In cystic fibrosis (CF), airway infections with Pseudomonas aeruginosa remain a key driver ...
    Advanced search

    Browse

    Communities & CollectionsIssue DateAuthorTitleSubjectDocument TypeThis CollectionIssue DateAuthorTitleSubjectDocument Type

    My Account

    Admin

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Follow Curtin

    • 
    • 
    • 
    • 
    • 

    CRICOS Provider Code: 00301JABN: 99 143 842 569TEQSA: PRV12158

    Copyright | Disclaimer | Privacy statement | Accessibility

    Curtin would like to pay respect to the Aboriginal and Torres Strait Islander members of our community by acknowledging the traditional owners of the land on which the Perth campus is located, the Whadjuk people of the Nyungar Nation; and on our Kalgoorlie campus, the Wongutha people of the North-Eastern Goldfields.